A BRCA2 mutation incorrectly mapped in the original BRCA2 reference sequence, is a common West Danish founder mutation disrupting mRNA splicing

被引:0
作者
Mads Thomassen
Inge Søkilde Pedersen
Ida Vogel
Thomas v. O. Hansen
Charlotte Brasch-Andersen
Claus L. Brasen
Dorthe Crüger
Lone Sunde
Finn C. Nielsen
Uffe B. Jensen
Marie Luise Bisgaard
Åke Borg
Anne-Marie Gerdes
Torben A. Kruse
机构
[1] Odense University Hospital,Department of Clinical Genetics
[2] Aarhus University Hospital,Department of Clinical Genetics
[3] Odense University Hospital,Department of Biochemistry and Pharmacology
[4] Aalborg University Hospital,Department of Biochemistry, Section of Molecular Diagnostics
[5] Rigshospitalet,Department of Clinical Biochemistry, Section of Genomic Medicine
[6] Aalborg Sygehus,Department of Clinical Genetics, Human Genetics
[7] Aarhus University Hospital,Department of Clinical Genetics
[8] Aarhus University,Department of Oncology, Clinical Sciences
[9] Vejle Hospital,Department of Clinical Genetics
[10] Lund University,Department of Cellular and Molecular Medicine
[11] Rigshospitalet,undefined
[12] Copenhagen University,undefined
来源
Breast Cancer Research and Treatment | 2011年 / 128卷
关键词
Hereditary breast cancer; BRCA2; 7845+1G>A; Founder mutation; Mutation age; SNP array; RT-PCR;
D O I
暂无
中图分类号
学科分类号
摘要
Inherited mutations in the tumor suppressor genes BRCA1 and BRCA2 predispose carriers to breast and ovarian cancer. The authors have identified a mutation in BRCA2, 7845+1G>A (c.7617+1G>A), not previously regarded as deleterious because of incorrect mapping of the splice junction in the originally published genomic reference sequence. This reference sequence is generally used in many laboratories and it maps the mutation 16 base pairs inside intron 15. However, according to the recent reference sequences the mutation is located in the consensus donor splice sequence. By reverse transcriptase analysis, loss of exon 15 in the final transcript interrupting the open reading frame was demonstrated. Furthermore, the mutation segregates with a cancer phenotype in 18 Danish families. By genetic analysis of more than 3,500 Danish breast/ovarian cancer risk families, the mutation was identified as the most common BRCA2 mutation in West Denmark, while it is rare in Central and East Denmark and not identified in South Sweden. Haplotype analysis using dense SNP arrays indicated a common founder of the mutation approximately 1,500 years ago.
引用
收藏
页码:179 / 185
页数:6
相关论文
共 134 条
[1]  
Gerdes AM(2002)Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50,302 women with breast cancer and 96,973 women without the disease Lancet 360 187-195
[2]  
Cruger DG(2006)Evaluation of two different models to predict BRCA1 and BRCA2 mutations in a cohort of Danish hereditary breast and/or ovarian cancer families Clin Genet 69 171-178
[3]  
Thomassen M(1997)Study of a single BRCA2 mutation with high carrier frequency in a small population Am J Hum Genet 60 1079-1084
[4]  
Kruse TA(1999)Three per cent of Norwegian ovarian cancers are caused by BRCA1 1675delA or 1135insA Eur J Cancer 35 779-781
[5]  
Thorlacius S(2009)A common Greenlandic Inuit BRCA1 RING domain founder mutation Breast Cancer Res Treat 115 69-76
[6]  
Sigurdsson S(1997)The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women Am J Hum Genet 60 505-514
[7]  
Bjarnadottir H(2008)BRCA1 and BRCA2 mutations in Danish families with hereditary breast and/or ovarian cancer Acta Oncol 47 772-777
[8]  
Olafsdottir G(2005)‘Indirect’ BRCA1/2 testing: a useful approach in hereditary breast and ovarian cancer families without a living affected relative Clin Genet 68 228-233
[9]  
Jonasson JG(2002)Integrated platform for detection of DNA sequence variants using capillary array electrophoresis Electrophoresis 23 1499-1511
[10]  
Tryggvadottir L(1995)Rapid detection of BRCA1 mutations by the protein truncation test Nat Genet 10 208-212